Using Decipher Genomic Classifier in diagnosis of Prostate Cancer
For men facing diagnosis of prostate cancer this study might be helpful.
This systematic review evaluated the available evidence supporting the clinical utility of the Decipher genomic classifier (GC). A total of 42 studies and more than 30,000 patients were included. The authors found that GC was independently prognostic for all study endpoints (adverse pathology, biochemical failure, metastasis, and cancer-specific and overall survival) in 24 studies.
The authors provide consistent evidence that this test helps identify which cancers are more or less aggressive, which in turn aids in personalized treatment decision–making. The utility of the GC is strongest for intermediate-risk prostate cancer and post-prostatectomy decision–making.
– Gautam Jayram, MD